Pharmaceutical company, AFT, has updated its operating profit guidance for the financial year ending in March to $23 million to $25m.
The new guidance, which includes a $6m license fee payment, represents an improvement over the previous range of $22m to $24m.
The update was attributed to lower than forecast sales in Australasia, as well as the decision to utilise the Hikma license fee income for growth investments.
AFT's managing director, Hartley Atkinson, expressed confidence in the company's prospects and said they would continue to invest for future growth.
AFT expects to declare a dividend for the financial year.
See more
